Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
08:21pm, Wednesday, 12'th Nov 2025
Fractyl Health, Inc. ( GUTS ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Brian Luque - Head of Investor Relations & Corporate Development Harith Rajagopalan - Co-Founder,
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-lab
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
07:00am, Wednesday, 05'th Nov 2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07:00am, Tuesday, 07'th Oct 2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the po
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang
05:14am, Wednesday, 01'st Oct 2025
Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 m
Fractyl Health, Inc. - Special Call
11:07am, Friday, 26'th Sep 2025
Fractyl Health, Inc. - Special Call Company Participants Brian Luque Harith Rajagopalan - Co-Founder, CEO & Director Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Res
Fractyl Health says experimental procedure helps maintain weight-loss in study
07:41am, Friday, 26'th Sep 2025
Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
07:05am, Friday, 26'th Sep 2025
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” o
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regai
Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward
06:05pm, Friday, 05'th Sep 2025
Fractyl Health's Revita offers a one-time procedure to maintain GLP-1 weight loss, with pivotal 45-patient trial data expected imminently. Early open-label results show Revita may significantly reduce
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
07:00am, Wednesday, 03'rd Sep 2025
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript
08:00pm, Tuesday, 12'th Aug 2025
Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian Luque - Corporate Participant Harith Rajagopalan - Co-Founder, CEO & Director
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
04:05pm, Tuesday, 12'th Aug 2025
Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita ® procedure sustained weight loss after GLP-1 discontinuation; i
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches t
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
08:30am, Wednesday, 06'th Aug 2025
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches t
